Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.58 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | STAT1 | P42224 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.57 |
| ▸ | ACP1 | P24666 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26034880 | 0.89 | CXCR2 (0.83) | CXCR2KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL6295875 | 0.89 | CXCR2 (0.79) | CXCR2KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL21858369 | 0.87 | CXCR2 (1.00) | CXCR2KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL21858353 | 0.86 | CXCR2 (0.82) | CXCR2KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL21858366 | 0.84 | CXCR2 (0.72) | CXCR2KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL27093075 | 0.84 | CXCR2 (0.72) | CXCR2KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL26034882 | 0.84 | CXCR2 (0.76) | CXCR2KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL4909104 | 0.84 | CXCR2 (0.76) | CXCR2KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL26034889 | 0.83 | CXCR2 (0.71) | CXCR2KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL21858361 | 0.83 | MAPT (0.77) | CXCR2KMT2AMEN1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | VHL, TP53, NUDT1 | CXCR2 1998/4885KMT2A 623/4885MEN1 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.